- Home
- RIGL vs BFZ Comparison
RIGL vs BFZ Comparison
Compare RIGL & BFZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BFZ
- Stock Information
- Founded
- RIGL 1996
- BFZ 2001
- Country
- RIGL United States
- BFZ United States
- Employees
- RIGL N/A
- BFZ N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BFZ Finance Companies
- Sector
- RIGL Health Care
- BFZ Finance
- Exchange
- RIGL Nasdaq
- BFZ Nasdaq
- Market Cap
- RIGL 335.5M
- BFZ 315.1M
- IPO Year
- RIGL 2000
- BFZ N/A
- Fundamental
- Price
- RIGL $38.85
- BFZ $10.40
- Analyst Decision
- RIGL Buy
- BFZ
- Analyst Count
- RIGL 5
- BFZ 0
- Target Price
- RIGL $38.20
- BFZ N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- BFZ 60.7K
- Earning Date
- RIGL 08-05-2025
- BFZ 01-01-0001
- Dividend Yield
- RIGL N/A
- BFZ 4.39%
- EPS Growth
- RIGL N/A
- BFZ N/A
- EPS
- RIGL 5.43
- BFZ 0.08
- Revenue
- RIGL $267,921,000.00
- BFZ N/A
- Revenue This Year
- RIGL $59.93
- BFZ N/A
- Revenue Next Year
- RIGL N/A
- BFZ N/A
- P/E Ratio
- RIGL $7.15
- BFZ $147.26
- Revenue Growth
- RIGL 105.62
- BFZ N/A
- 52 Week Low
- RIGL $12.66
- BFZ $9.86
- 52 Week High
- RIGL $43.72
- BFZ $12.31
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- BFZ 37.41
- Support Level
- RIGL $39.00
- BFZ $10.55
- Resistance Level
- RIGL $42.08
- BFZ $10.44
- Average True Range (ATR)
- RIGL 2.32
- BFZ 0.08
- MACD
- RIGL -0.37
- BFZ -0.00
- Stochastic Oscillator
- RIGL 53.26
- BFZ 21.59
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BFZ BlackRock California Municipal Income Trust
Blackrock CA Muni Income Tr is a United States-based closed-end management investment company. The investment objective of the trust is to provide current income exempt from regular U.S. federal income tax. The trust seeks to achieve its investment objectives by investing a majority of its total assets in municipal bonds.